Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass. – August 22, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall […]